Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Masimo

Apple stops selling latest Apple Watch after losing patent case

Apple said sales of its Series 9 and Ultra 2 smartwatches would be halted this week after it lost a case over whether the tech giant stole a patented blood oxygen feature from another company.

WEKU

Apple Pauses US Sale Of Latest Watch Models Over Patent Clash

Apple on Monday said it will stop selling some of its smartwatch models in the United States while it fights a patent battle over technology for detecting blood oxygen levels.

International Business Times

Apple halting Apple Watch 9 and Apple Watch Ultra 2 sales this week over patent dispute — what it means for you

Following an ITC patent dispute ruling, the Apple Watch Series 9 and Apple Watch Ultra 2 are being pulled from the Apple Store. The ban begins on December 21 for Apple.com.

Tom’s Guide

From analysis to the latest developments in health,
read the most diverse news in one place.

Apple Watch Ultra 2 and Series 9 sales ban: all your questions, answered

Apple Watch Series 9 and Ultra 2 are about to be taken off shelves - but can you still get one in time for the holidays?

TechRadar

Apple is about to stop selling the Apple Watch Series 9 and Ultra 2 – here are all the details

It follows a patent dispute about the medical sensors.

TechRadar

Biden must decide whether patent-infringing Apple watches can be imported into the U.S. from China by Christmas–but Congress could neuter America’s ability to protect its IP altogether

The U.S. International Trade Commission (ITC) recently issued an order that could prohibit imports of some Apple Watch products.

Fortune

Apple Watch faces US ban over patent dispute — what you need to know

A patent dispute over the Apple Watch's pulse oximeter tech may lead to an outright ban in the US.

Tom’s Guide

Read news from The Economist, FT, and more,
with one subscription

Masimo Surges After Winning A Potential $100 Million Battle Against Apple

Masimo could take a bite out of Apple's sales, an analyst said Friday as MASI stock surged after winning a patent battle.

Investors Business Daily

Masimo Crashes To Four-Year Low; Why It Could Take 'Months To Regain Footing'

It could take Masimo months to regain its footing, an analyst said Tuesday as investors hammered MASI stock on a massive sales miss.

Investors Business Daily

I test headphones for a living and these are the wireless earbuds I'm most excited for in 2023

My favorite wireless earbuds from last year are about to be upstaged by two new models from Denon using the same sound tech for the ultimate personalized listening experience.

Tom’s Guide

Denon PerL earbuds offer Per(sonalized) L(istening) with new proprietary tech

The Denon PerL Pro and Denon PerL use proprietary tech to analyse the user's ear for a tailored listening experience'.

TechRadar

Denon's new wireless earbuds are Bose and Sony rivals that can measure your hearing

The new PerL wireless buds challenge the Sony and Bose class-leaders with strong codec support, battery life, ANC and unique tech for a bespoke audio profile

What Hi-Fi?

$1.8 billion Apple Watch lawsuit crumbles as mistrial called

A lawsuit alleging Apple stole trade secrets for future Apple Watch sensors has been called as a mistrial after jurors failed to reach a verdict.

iMore

Shareholder activism's rise comes with more failures

Experts say it's not a sign of an ESG backlash.

Fortune

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

How Masimo Is Taking On Electronics Giant Apple — And Winning

Masimo stock surged Wednesday after a U.S. judge ruled Apple infringed on two patents protecting Masimo's blood-oxygen-reading technology.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022

Upgrades

Benzinga

Masimo's (MASI) Q2 Earnings Surpass Estimates, Margins Down

Masimo Corporation (NASDAQ: MASI) delivered adjusted earnings per share (ETF:EPS) of $1.35 in the second quarter of 2022, up 43.6% year over year. The figure surpassed the Zacks Consensus Estimate by 13.5%.

Benzinga

Masimo's Return on Invested Capital Insights

According to Benzinga Pro, during Q1, Masimo (NASDAQ:MASI) earned $46.59 million, a 31.74% increase from the preceding quarter. Masimo's sales decreased to $304.24 million, a 7.12% change since Q4.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

7 Analysts Have This to Say About Masimo

Masimo (NASDAQ:MASI) has observed the following analyst ratings within the last quarter:

Benzinga

Masimo Posts Better Than Expected Q1 Earnings Despite 'Unexpected' Supply Chain Issues

Masimo Corp's (NASDAQ:MASI) Q1 revenue increased 1.7% Y/Y (+3.2% on a constant currency basis) to $304.2 million, beating the consensus of $303.83 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 75,700 in Q1 of 2022. The adjusted operating margin remained unchanged at 22.9%. The company reported…

Benzinga

Masimo's Earnings Outlook

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Masimo will report an earnings per share (EPS) of $0.87.

StockNews.com

2 Stocks Down 50% Year-to-Date That Are Buys Now

The probability of aggressive interest rate increases by the Fed later this year, and the Ukraine-Russia war, have weighed on the stock market so far this year. However, April has traditionally been one of the best months of the year for stocks. Therefore, we think the recent market dip could…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022

Upgrades

StockNews.com

Down by More Than 25%, Grab These 3 Stocks Before They Rebound

Following a disappointing stock market performance since the beginning of the year, progress in peace talks between Russia and Ukraine and an expected steady economic recovery despite the likelihood of more interest rate hikes have improved investor sentiment of late. Therefore, we think it could be wise to bet on…

Benzinga

The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall

Here's a roundup of top developments in the biotech space over the last 24 hours:

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.